Caxton Associates
Caxton Associates LP is a $7.6 billion New York-based hedge fund, founded in 1983 by Bruce Kovner.
Caxton Associates' primary business is to manage client and proprietary capital through global macro hedge fund strategies as well as other alternative investment disciplines.
Caxton employs over 205 people at its offices in New York, Princeton, NJ and London.
View Older Stories View More Recent Stories
-
Advanced Design & Manufacturing Toronto Wraps with Doubled Attendance
-
Form 13F-HR CAXTON ASSOCIATES LP For: Sep 30
-
Form 13F-HR CAXTON CORP For: Sep 30
-
Exclusive-Hedge fund Caxton wins on bond rout to claw back performance losses - sources
-
Mind Your Money: 5 Tips From Pocket Money Card nimbl to Spot and Stop Online Fraud
-
Trumid names Jason Quinn as Global Head of Sales as company continues to expand its trading footprint
-
IBN Announces Media Sponsorship of the 49th Annual New Orleans Investment Conference
-
Cinctive Expands Global Macro and Healthcare Investment Teams as Firm Marks Four Year Anniversary
-
Form 13F-HR CAXTON ASSOCIATES LP For: Jun 30
-
Form 13F-HR CAXTON CORP For: Jun 30
-
Multi-Manager Cinctive Capital Management Appoints Veteran Pension Fund Manager and Investor Michael Haddad as Deputy Chief Investment Officer
-
Form 13F-HR CAXTON ASSOCIATES LP For: Mar 31
-
Form 13F-HR CAXTON CORP For: Mar 31
-
Fulton Financial Advisors and Fulton Private Bank Hire Mark Hoffman, Ph.D., CFA, as Chief Investment Officer
-
Piper Sandler Expands Consumer Equity Research Group with Addition of Brian Mullan
-
Tech Veteran Apjit Walia Launching Global Macro and Technology Hedge Fund DVN Capital
-
Form D Caxton Macro Ltd
-
Form D/A Caxton Macro (USA) LLC
-
Form D/A Caxton Global Investment
-
Form D Caxton Global Investment
-
Form D Caxton Global Investment
-
Form D Caxton Dynamis Ltd
-
Form D/A Caxton Dynamis (USA)
-
Form D Caxton Advantage Ltd
-
Form D/A Caxton Advantage (USA)
-
Vivo Capital Names John Massad Managing Director, Business Development
-
Form 13F-HR CAXTON ASSOCIATES LP For: Dec 31
-
Form SC 13G/A Rezolute, Inc. Filed by: CAXTON CORP
-
Form SC 13G/A Cardiff Oncology, Inc. Filed by: CAXTON CORP
-
Form SC 13G/A Addex Therapeutics Ltd. Filed by: CAXTON CORP
-
Form SC 13G/A Xeris Biopharma Holdings Filed by: CAXTON CORP
-
Form 13F-HR CAXTON CORP For: Dec 31
-
Top hedge funds earned sharply less for clients in 2022, LCH data shows
-
Macro hedge funds end 2022 on high, many others lose big, investors say
-
Form 13F-HR CAXTON ASSOCIATES LP For: Sep 30
-
Form 13F-HR CAXTON CORP For: Sep 30
-
Dollar higher but gains in check as risk appetite rebounds
-
Galvanize Climate Solutions Announces New Senior, Analyst Hires
-
Whipsawed forex traders say currency moves 'remarkable', resemble casino
-
ECB raises rates by unprecedented 75 basis points
-
Dollar rises on risk aversion; euro revisits parity
-
Form 13F-HR CAXTON ASSOCIATES LP For: Jun 30
-
Form 13F-HR CAXTON CORP For: Jun 30
-
Euro strengthens after ECB hikes faster than flagged
-
Dollar dips as rate hike bets ease
-
Euro falls below parity for the first time in 2 decades
-
Muted start to new quarter for European equities as recession worries weigh
-
Rally House Brings 7th Store to Cleveland Market
-
Dollar index jumps to two-decade high as traders await Fed rate move
-
Dollar recovers ground as risk appetite fades

